Kintor Pharmaceutical Ltd. has announced the completion of patient enrollment in the Phase III stage of a pivotal clinical trial for KX-826 tincture 1.0%, aimed at treating male adult androgenetic alopecia (AGA) in China. The trial enrolled 666 patients and is characterized by a multi-center, randomized, double-blind, vehicle-controlled design. This Phase III stage involves a 24-week treatment period, followed by a 2-week safety observation period, across 25 clinical research centers in China. The Phase II stage of the trial previously met its primary endpoints, showing statistically significant and clinically meaningful outcomes in terms of efficacy and safety. The completion of the Phase III stage is anticipated by early 2026. Results from this stage have not yet been presented.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。